- Trials with a EudraCT protocol (44)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (1)
44 result(s) found for: Acute visual loss.
Displaying page 1 of 3.
EudraCT Number: 2015-003079-31 | Sponsor Protocol Number: QRK207 | Start Date*: 2016-10-20 | |||||||||||
Sponsor Name:Quark Pharmaceuticals Inc. | |||||||||||||
Full Title: A PHASE 2/3, RANDOMIZED, DOUBLE-MASKED, SHAMCONTROLLED TRIAL OF QPI-1007 DELIVERED BY SINGLE OR MULTI-DOSE INTRAVITREAL INJECTION(S) TO SUBJECTS WITH ACUTE NONARTERITIC ANTERIOR ISCHEMIC OPTIC NEU... | |||||||||||||
Medical condition: NAION typically presents as an abrupt, painless monocular vision loss. Visual loss varies widely, ranging from visual field loss only to complete blindness. The neuronal degeneration process in N... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-005592-14 | Sponsor Protocol Number: 26 | Start Date*: 2006-07-27 |
Sponsor Name:IFSgGmbH, Institute for clinical research | ||
Full Title: Double blind, placebo-controlled study to determine the safety and efficacy of erythropoietin as an add-on therapy to methylprednisolone in subjects with acute autoimmune optic neuritis (VISION PRO... | ||
Medical condition: Multiple sclerosis (MS) is a chronic disease of the central nervous system.Optic neuritis represents one of the most common and frequently the first clinical manifestation of MS. Optic neuritis is ... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-001145-40 | Sponsor Protocol Number: P17-03 | Start Date*: 2019-11-06 | ||||||||||||||||
Sponsor Name:Centre Hospitalier National d’Ophtalmologie des Quinze-Vingts | ||||||||||||||||||
Full Title: French prospective open label phase II randomized non-comparative study of SC tocilizumab associated with IV pulse steroid versus IV pulse steroid alone for the treatment of acute anterior ischemic... | ||||||||||||||||||
Medical condition: Giant cell arteritis, acute anterior ischemic optic neuropathy | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-005113-39 | Sponsor Protocol Number: SSP-2 | Start Date*: 2013-04-08 |
Sponsor Name:Universitätsklinik für Neurologie, Medizinische Universität Wien | ||
Full Title: A Randomized, Placebo-Controlled, Double-Blind, Phase IIa Study of Amiloride in the Treatment of Acute Autoimmune Optic Neuritis | ||
Medical condition: Optic neuritis is among the most common first symptoms of multiple sclerosis leading to significant atrophy of the optic nerve within a short period of time, thus reflecting neurodegneration. | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: AT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2018-001756-35 | Sponsor Protocol Number: 16/0163 | Start Date*: 2019-06-21 | |||||||||||
Sponsor Name:University of California, San Francisco | |||||||||||||
Full Title: A Randomized, Double-Blind, Parallel-Group, Placebo Controlled Trial to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of Clemastine Fumarate as a Remyelinating Agent in Acute Opti... | |||||||||||||
Medical condition: acute optic neuritis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-000183-29 | Sponsor Protocol Number: REVISION | Start Date*: 2022-03-09 | |||||||||||
Sponsor Name:Eberhard-Karls University Tübingen, Med. Fac. rep. by University Hospital and its Commercial Director | |||||||||||||
Full Title: Early Reperfusion Therapy with Intravenous Alteplase for Recovery of VISION in Acute Central Retinal Artery Occlusion (REVISION) - A double-blind randomized placebo-controlled phase III proof-of-co... | |||||||||||||
Medical condition: Acute non-arteritic central retinal artery occlusion (CRAO) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-002061-22 | Sponsor Protocol Number: RC17_0061 | Start Date*: 2017-09-12 | |||||||||||
Sponsor Name:CHU de Nantes | |||||||||||||
Full Title: A phase III randomized, blind, double dummy, multicenter study assessing the efficacy and safety of IV thrombolysis (alteplase) in patients with acute central retinal artery occlusion | |||||||||||||
Medical condition: acute central retinal artery occlusion | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-003029-40 | Sponsor Protocol Number: IOBA-01-2016 | Start Date*: 2017-02-14 |
Sponsor Name:IOBA - University of Valladolid | ||
Full Title: Phase II safety assessment of intravitreal injection of mesenchymal stem cells for acute non arteritic anterior ischemic optic neuropathy (NAION) | ||
Medical condition: Non arteritic anterior ischemic optic neuropathy (NAION) | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2020-003147-29 | Sponsor Protocol Number: ACT-01_P2_01 | Start Date*: 2020-11-06 |
Sponsor Name:ACCURE TX FRANCE SASU | ||
Full Title: A two-arm randomized double-blind placebo-controlled monocentric study to evaluate the safety and tolerability of ACT-01 compared to placebo in patients with acute optic neuritis | ||
Medical condition: Subjects from 18 to 60 years old with a diagnosis of a unilateral Acute Optic Neuritis with a demyelinating origin, whose symptoms have appeared in the last 10 days before randomization and whose e... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2011-003475-11 | Sponsor Protocol Number: UCL/11/0083 | Start Date*: 2011-11-15 | |||||||||||
Sponsor Name:University College London (UCL) | |||||||||||||
Full Title: A phase II double-blind, randomised, placebo-controlled trial of neuroprotection with phenytoin in acute optic neuritis | |||||||||||||
Medical condition: Acute demyelinating optic neuritis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-002968-27 | Sponsor Protocol Number: CFTY720D2402 | Start Date*: 2013-01-29 | |||||||||||
Sponsor Name:Novartis Farmaceutica, S.A | |||||||||||||
Full Title: A 48-week, double-blind, randomized, multi-center, parallelgroup study comparing structural changes in the retina and evolution of visual function after immediate versus delayed treatment with fing... | |||||||||||||
Medical condition: acute demyelinating optic neuritis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) IT (Prematurely Ended) GB (Completed) DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-002780-16 | Sponsor Protocol Number: 8.4 | Start Date*: 2012-06-11 |
Sponsor Name:Karolinska Institutet | ||
Full Title: PROLOGUES - Prehospital lowering of glucose in Stroke | ||
Medical condition: Patients with hyperglycemia and symptoms of acute stroke will be randomized to either subcutaneous injection with 10ug of Byetta or standard care. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: View results |
EudraCT Number: 2015-004405-16 | Sponsor Protocol Number: SNT-IV-005 | Start Date*: 2016-03-16 | |||||||||||
Sponsor Name:Santhera Pharmaceuticals (Switzerland) Limited | |||||||||||||
Full Title: External Natural History Controlled, open-Label Intervention Study to Assess the Efficacy and Safety of Long-Term Treatment with Raxone® in Leber’s Hereditary Optic Neuropathy (LHON) | |||||||||||||
Medical condition: Leber’s Hereditary Optic Neuropathy / LHON is a maternally inherited loss of vision due to atrophy of the optic nerve. It typically presents in young adults, mostly men, as painless acute or subacu... | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) DE (Completed) BE (Completed) PT (Completed) ES (Completed) BG (Completed) PL (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-006291-39 | Sponsor Protocol Number: 215ON201 | Start Date*: 2012-10-15 | |||||||||||
Sponsor Name:Biogen Idec Research Limited | |||||||||||||
Full Title: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Subjects With First Episode of Acute Optic Neur... | |||||||||||||
Medical condition: Acute Optic Neuritis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) BE (Completed) DE (Completed) CZ (Completed) GB (Completed) HU (Completed) ES (Completed) IT (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-006664-24 | Sponsor Protocol Number: INVEX-CLIN-IIH-301 | Start Date*: 2023-04-20 | |||||||||||
Sponsor Name:Invex Therapeutics Ltd. | |||||||||||||
Full Title: A Phase III randomised, placebo-controlled, double-blind, multi-centre, clinical trial to determine the efficacy and safety of Presendin in idiopathic intracranial hypertension | |||||||||||||
Medical condition: Idiopathic intracranial hypertension | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Prematurely Ended) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-014269-25 | Sponsor Protocol Number: A0081096 | Start Date*: 2009-12-18 | |||||||||||
Sponsor Name:Pfizer Inc | |||||||||||||
Full Title: PROSPECTIVE RANDOMIZED 12-WEEK CONTROLLED STUDY OF VISUAL FIELD CHANGE IN SUBJECTS WITH PARTIAL SEIZURES RECEIVING PREGABALIN OR PLACEBO | |||||||||||||
Medical condition: EPILEPSY WITH PARTIAL SEIZURE | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) CZ (Completed) PL (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-008135-28 | Sponsor Protocol Number: 01-281108 | Start Date*: 2009-04-16 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Hull and East Yorkshire NHS Hospitals Trust | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: Effect of Sildenafil on Pulmonary Artery Pressure during hypoxia and exercise in Chronic Heart Failure | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: We will investigate the effect of sildenafil on pulmonary artery pressure in Heart failure patients (impaired heart function). Patients will be recruited from the Heart Failure clinic at Castle Hil... | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2022-002385-32 | Sponsor Protocol Number: APHP211057 | Start Date*: 2022-08-31 |
Sponsor Name:Assistance Publique – Hôpitaux de Paris (AP-HP) | ||
Full Title: Immediate versus delayed treatment with azathioprine or rituximab in anti-myelin oligodendrocytes glycoprotein (anti-MOG) antibodies associated acute demyelinating syndromes in children: a randomiz... | ||
Medical condition: myelin oligodendrocytes glycoprotein antibody associated diseases (MOGAD) | ||
Disease: | ||
Population Age: Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2010-018498-39 | Sponsor Protocol Number: VIDEO2009 | Start Date*: 2010-07-01 | |||||||||||||||||||||
Sponsor Name:Erasmus Medical Center | |||||||||||||||||||||||
Full Title: VItamin D treatment Effect on retinal nerve fiber loss after Optic neuritis | |||||||||||||||||||||||
Medical condition: Optic neuritis | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-002179-27 | Sponsor Protocol Number: AUT032063 | Start Date*: 2014-08-29 | |||||||||||
Sponsor Name:Autifony Therapeutics Limited | |||||||||||||
Full Title: A Balanced Randomised Placebo Controlled Double-blind Phase IIa Study to Investigate the Efficacy and Safety of AUT00063 Versus Placebo in Subjective Tinnitus | |||||||||||||
Medical condition: Subjects suffering with noise and/or age-related tinnitus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
